Beyond The Watershed: Gene Therapy Investment And Promise
An Interview With Janet Lambert, CEO Of The Alliance For Regenerative Medicine
Janet Lambert, CEO of the Alliance of Regenerative Medicines recently spoke to In Vivo about the tremendous levels of investment the cell and gene therapy industries are attracting, as well as reasons why Europe excels at incubating advanced product development.
You may also be interested in...
The European Medicines Agency's draft guideline on investigational advanced therapy medicinal products makes a clear distinction between exploratory and confirmatory clinical trials as the classical approach of distinguishing between various stages of a clinical trial is not as well defined for such products.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.